Cargando…
Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis
OBJECTIVE: To determine whether lipids and apolipoproteins predict prognosis of patients with amyotrophic lateral sclerosis in a cohort study of 99 patients with amyotrophic lateral sclerosis who were diagnosed during 2015 to 2018 and followed up until October 31, 2018, at the Neurology Clinic in Ka...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7274849/ https://www.ncbi.nlm.nih.gov/pubmed/32221024 http://dx.doi.org/10.1212/WNL.0000000000009322 |
_version_ | 1783542672609247232 |
---|---|
author | Ingre, Caroline Chen, Lin Zhan, Yiqiang Termorshuizen, Jet Yin, Li Fang, Fang |
author_facet | Ingre, Caroline Chen, Lin Zhan, Yiqiang Termorshuizen, Jet Yin, Li Fang, Fang |
author_sort | Ingre, Caroline |
collection | PubMed |
description | OBJECTIVE: To determine whether lipids and apolipoproteins predict prognosis of patients with amyotrophic lateral sclerosis in a cohort study of 99 patients with amyotrophic lateral sclerosis who were diagnosed during 2015 to 2018 and followed up until October 31, 2018, at the Neurology Clinic in Karolinska University Hospital in Stockholm, Sweden. METHODS: Total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein AI, apolipoprotein B, and lipid ratios were measured at the time of amyotrophic lateral sclerosis diagnosis or shortly thereafter. Death after amyotrophic lateral sclerosis diagnosis was used as the main outcome. The Cox model was used to estimate hazard ratios with 95% confidence intervals of death after amyotrophic lateral sclerosis diagnosis, after controlling for sex, age at diagnosis, site of symptom onset, diagnostic delay, body mass index, Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised score, and progression rate. RESULTS: A 1-SD increase of total cholesterol (hazard ratio 0.60, 95% confidence interval 0.41–0.89, p = 0.01), low-density lipoprotein cholesterol (hazard ratio 0.64, 95% confidence interval 0.44–0.92, p = 0.02), low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio (hazard ratio 0.65, 95% confidence interval 0.46–0.92, p = 0.02), apolipoprotein B (hazard ratio 0.62, 95% confidence interval 0.44–0.88, p = 0.01), or apolipoprotein B/apolipoprotein AI ratio (hazard ratio 0.61, 95% confidence interval 0.43–0.86, p < 0.01) was associated with a lower risk of death after amyotrophic lateral sclerosis diagnosis. A dose-response relationship was also noted when these biomarkers were analyzed as categorical variables. CONCLUSIONS: Lipids and apolipoproteins are important prognostic indicators for amyotrophic lateral sclerosis and should be monitored at the diagnosis of amyotrophic lateral sclerosis. |
format | Online Article Text |
id | pubmed-7274849 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-72748492020-06-23 Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis Ingre, Caroline Chen, Lin Zhan, Yiqiang Termorshuizen, Jet Yin, Li Fang, Fang Neurology Article OBJECTIVE: To determine whether lipids and apolipoproteins predict prognosis of patients with amyotrophic lateral sclerosis in a cohort study of 99 patients with amyotrophic lateral sclerosis who were diagnosed during 2015 to 2018 and followed up until October 31, 2018, at the Neurology Clinic in Karolinska University Hospital in Stockholm, Sweden. METHODS: Total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein AI, apolipoprotein B, and lipid ratios were measured at the time of amyotrophic lateral sclerosis diagnosis or shortly thereafter. Death after amyotrophic lateral sclerosis diagnosis was used as the main outcome. The Cox model was used to estimate hazard ratios with 95% confidence intervals of death after amyotrophic lateral sclerosis diagnosis, after controlling for sex, age at diagnosis, site of symptom onset, diagnostic delay, body mass index, Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised score, and progression rate. RESULTS: A 1-SD increase of total cholesterol (hazard ratio 0.60, 95% confidence interval 0.41–0.89, p = 0.01), low-density lipoprotein cholesterol (hazard ratio 0.64, 95% confidence interval 0.44–0.92, p = 0.02), low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio (hazard ratio 0.65, 95% confidence interval 0.46–0.92, p = 0.02), apolipoprotein B (hazard ratio 0.62, 95% confidence interval 0.44–0.88, p = 0.01), or apolipoprotein B/apolipoprotein AI ratio (hazard ratio 0.61, 95% confidence interval 0.43–0.86, p < 0.01) was associated with a lower risk of death after amyotrophic lateral sclerosis diagnosis. A dose-response relationship was also noted when these biomarkers were analyzed as categorical variables. CONCLUSIONS: Lipids and apolipoproteins are important prognostic indicators for amyotrophic lateral sclerosis and should be monitored at the diagnosis of amyotrophic lateral sclerosis. Lippincott Williams & Wilkins 2020-04-28 /pmc/articles/PMC7274849/ /pubmed/32221024 http://dx.doi.org/10.1212/WNL.0000000000009322 Text en Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Article Ingre, Caroline Chen, Lin Zhan, Yiqiang Termorshuizen, Jet Yin, Li Fang, Fang Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis |
title | Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis |
title_full | Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis |
title_fullStr | Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis |
title_full_unstemmed | Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis |
title_short | Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis |
title_sort | lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7274849/ https://www.ncbi.nlm.nih.gov/pubmed/32221024 http://dx.doi.org/10.1212/WNL.0000000000009322 |
work_keys_str_mv | AT ingrecaroline lipidsapolipoproteinsandprognosisofamyotrophiclateralsclerosis AT chenlin lipidsapolipoproteinsandprognosisofamyotrophiclateralsclerosis AT zhanyiqiang lipidsapolipoproteinsandprognosisofamyotrophiclateralsclerosis AT termorshuizenjet lipidsapolipoproteinsandprognosisofamyotrophiclateralsclerosis AT yinli lipidsapolipoproteinsandprognosisofamyotrophiclateralsclerosis AT fangfang lipidsapolipoproteinsandprognosisofamyotrophiclateralsclerosis |